EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.45 USD | -0.91% |
|
-5.43% | +13.38% |
| Apr. 17 | Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 | MT |
| Apr. 17 | Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating | MT |
Financials (USD)
| Sales 2024 * | 6.52B | Sales 2025 * | 7.15B | Capitalization | 52.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.82B | EV / Sales 2024 * | 7.7 x |
| Net cash position 2024 * | 1.87B | Net cash position 2025 * | 3.09B | EV / Sales 2025 * | 6.84 x |
| P/E ratio 2024 * |
32.2
x | P/E ratio 2025 * |
28.8
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | -0.91% | ||
| 1 week | -5.43% | ||
| Current month | -9.53% | ||
| 1 month | -6.89% | ||
| 3 months | +16.13% | ||
| 6 months | +24.01% | ||
| Current year | +13.38% |
1 week
85.98
91.73
1 month
85.9896.12
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
12.86131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
| Chairman | 71 | 99-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Director/Board Member | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 44 M€ | +1.09% | - | |
| 2.34% | 18 M€ | +1.40% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 86.45 | -0.91% | 3,122,037 |
| 24-04-17 | 87.24 | -3.12% | 2,878,118 |
| 24-04-16 | 90.05 | +0.95% | 2,640,500 |
| 24-04-15 | 89.2 | -1.20% | 2,863,151 |
| 24-04-12 | 90.28 | -1.24% | 3,155,519 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.45
USD
Average target price
94.48
USD
Spread / Average Target
+9.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.38% | 52.04B | |
| +2.02% | 207B | |
| +2.17% | 175B | |
| +10.45% | 132B | |
| +16.62% | 99.1B | |
| -4.37% | 60.89B | |
| -6.33% | 45.48B | |
| -4.74% | 38.81B | |
| +9.89% | 38.77B | |
| +3.25% | 26.09B |
- Stock Market
- Equities
- EW Stock
